Significant Advancements in AHB-137 Development
AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together known as AusperBio), a clinical-stage biotechnology company, have made important strides in their ongoing clinical efforts for AHB-137. This therapeutic aims at achieving a functional cure for chronic Hepatitis B (CHB) through an innovative approach utilizing antisense oligonucleotides (ASOs).
Details of the Phase IIb Study
The Phase IIb trial of AHB-137 has seen active patients over two distinct treatment durations—16 weeks and 24 weeks. Each treatment duration included 32 participants. During the trial, the 16-week cohort underwent an initial 8-week double-blind placebo lead-in period. AusperBio is pleased to announce that the dosing phase has been completed for both cohorts, and crucially, the study has been unblinded.
Acknowledgement of Challenges and Successes
In the words of Dr. Guofeng Cheng, Co-founder and CEO of AusperBio, “The progress of AHB-137 underscores our commitment towards finding an effective treatment for chronic hepatitis B.” His affirmation stems from the encouraging efficacy data observed in the Phase IIb study thus far. He also noted that AHB-137 has proven to be well tolerated among the patients involved.
Phase IIa Data Encourages Further Investigation
This advancement comes soon after the interim results of the Phase IIa study were shared during a prestigious conference. The positive response signifies AusperBio's growing capability in addressing the pressing demand for a CHB functional cure.
Reinforcement of Clinical Findings
Dr. Chris Yang, Co-founder and CSO, remarked that the preliminary findings from the Phase IIb study serve to enhance the exciting Phase IIa results, particularly in terms of HBsAg loss and seroconversion. Plans are underway to present these interim results to an international forum soon.
Gratitude for Collaborative Efforts
The success of the Phase IIb trial stands on the shoulders of countless professionals. AusperBio extends heartfelt thanks to the principal investigators, clinical staff, study participants, and the dedicated team who have all played a part in moving this initiative forward.
About AHB-137 and its Role
AHB-137 is a cutting-edge antisense oligonucleotide developed using AusperBio's Med-Oligo™ ASO technology platform, specifically engineered to tackle chronic hepatitis B. The promising preclinical results and the data shared during Phase 1 highlight its potential in pioneering new treatment pathways. Currently, AHB-137 is also involved in a Phase 1b trial across multiple international locations, demonstrating the broad ambition of its development.
Company Mission and Vision
AusperBio is dedicated to pioneering oligonucleotide-based therapies aimed at transforming patient outcomes. With a focus on curing chronic hepatitis B, AusperBio has developed its proprietary Med-Oligo™ ASO platform, designed to improve the capabilities of ASO therapies considerably. This innovative approach not only targets hepatitis B but also holds promise for treating various other serious conditions including viral infections, genetic disorders, and immune-related diseases.
Frequently Asked Questions
What is AHB-137?
AHB-137 is an antisense oligonucleotide therapeutic aiming for a functional cure for chronic hepatitis B.
What happened in the Phase IIb study?
The dosing in both 16-week and 24-week cohorts was successfully completed, with the study now unblinded.
Who leads AusperBio?
Dr. Guofeng Cheng serves as the Co-founder and CEO, with Dr. Chris Yang as Co-founder and CSO.
What can we expect from future AHB-137 studies?
AusperBio plans to present interim data from the Phase IIb study at upcoming international conferences.
How does AusperBio's technology stand out?
The proprietary Med-Oligo™ ASO platform enhances the design and delivery of ASO therapeutics, targeting various diseases.
